OTCMKTS:WWHC

W World Competitors

$6.09
+0.29 (+5.00 %)
(As of 04/8/2021 03:03 PM ET)
Add
Compare
Today's Range
$2.10
Now: $6.09
$6.10
50-Day Range
$2.30
MA: $3.81
$6.09
52-Week Range
$1.00
Now: $6.09
$27.40
Volume1,231 shs
Average Volume426 shs
Market Capitalization$1.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.97

Competitors

W World (OTCMKTS:WWHC) Vs. PVTTF, KAYS, IPCIF, ISCO, BCTXF, and WCUI

Should you be buying WWHC stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to W World, including Pivotal Therapeutics (PVTTF), Kaya (KAYS), Intellipharmaceutics International (IPCIF), International Stem Cell (ISCO), BriaCell Therapeutics (BCTXF), and Wellness Center USA (WCUI).

Pivotal Therapeutics (OTCMKTS:PVTTF) and W World (OTCMKTS:WWHC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Risk & Volatility

Pivotal Therapeutics has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, W World has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Pivotal Therapeutics and W World, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pivotal Therapeutics0000N/A
W World0000N/A

Insider and Institutional Ownership

0.1% of W World shares are owned by institutional investors. 61.1% of W World shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Pivotal Therapeutics and W World's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pivotal TherapeuticsN/AN/AN/A
W WorldN/AN/AN/A

Valuation and Earnings

This table compares Pivotal Therapeutics and W World's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pivotal TherapeuticsN/AN/AN/AN/AN/A
W WorldN/AN/AN/AN/AN/A

Summary

W World beats Pivotal Therapeutics on 3 of the 3 factors compared between the two stocks.

Kaya (OTCMKTS:KAYS) and W World (OTCMKTS:WWHC) are both small-cap consumer discretionary companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Valuation and Earnings

This table compares Kaya and W World's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kaya$1.01 million6.21$7.80 millionN/AN/A
W WorldN/AN/AN/AN/AN/A

Kaya has higher revenue and earnings than W World.

Profitability

This table compares Kaya and W World's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kaya-1,558.07%N/A-586.93%
W WorldN/AN/AN/A

Risk & Volatility

Kaya has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500. Comparatively, W World has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Kaya and W World, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kaya01002.00
W World0000N/A

Insider and Institutional Ownership

0.1% of W World shares are owned by institutional investors. 61.1% of W World shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

W World beats Kaya on 5 of the 6 factors compared between the two stocks.

Intellipharmaceutics International (OTCMKTS:IPCIF) and W World (OTCMKTS:WWHC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares Intellipharmaceutics International and W World's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Intellipharmaceutics International$3.48 million1.60$-8,090,000.00N/AN/A
W WorldN/AN/AN/AN/AN/A

W World has lower revenue, but higher earnings than Intellipharmaceutics International.

Profitability

This table compares Intellipharmaceutics International and W World's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Intellipharmaceutics International-232.11%N/A-81.71%
W WorldN/AN/AN/A

Risk and Volatility

Intellipharmaceutics International has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, W World has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Intellipharmaceutics International and W World, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Intellipharmaceutics International0000N/A
W World0000N/A

Institutional & Insider Ownership

0.1% of W World shares are held by institutional investors. 61.1% of W World shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

W World beats Intellipharmaceutics International on 5 of the 6 factors compared between the two stocks.

International Stem Cell (OTCMKTS:ISCO) and W World (OTCMKTS:WWHC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares International Stem Cell and W World's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
International Stem Cell$9.47 million0.58$-4,260,000.00N/AN/A
W WorldN/AN/AN/AN/AN/A

W World has lower revenue, but higher earnings than International Stem Cell.

Profitability

This table compares International Stem Cell and W World's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
International Stem Cell-55.56%N/A-72.21%
W WorldN/AN/AN/A

Risk and Volatility

International Stem Cell has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Comparatively, W World has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for International Stem Cell and W World, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
International Stem Cell0000N/A
W World0000N/A

Institutional & Insider Ownership

0.1% of W World shares are held by institutional investors. 81.7% of International Stem Cell shares are held by insiders. Comparatively, 61.1% of W World shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

W World beats International Stem Cell on 4 of the 6 factors compared between the two stocks.

BriaCell Therapeutics (OTCMKTS:BCTXF) and W World (OTCMKTS:WWHC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares BriaCell Therapeutics and W World's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BriaCell TherapeuticsN/AN/A$-3,680,000.00N/AN/A
W WorldN/AN/AN/AN/AN/A

Profitability

This table compares BriaCell Therapeutics and W World's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BriaCell TherapeuticsN/AN/A-786.77%
W WorldN/AN/AN/A

Risk and Volatility

BriaCell Therapeutics has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, W World has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for BriaCell Therapeutics and W World, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BriaCell Therapeutics0000N/A
W World0000N/A

Institutional & Insider Ownership

0.1% of BriaCell Therapeutics shares are held by institutional investors. Comparatively, 0.1% of W World shares are held by institutional investors. 61.1% of W World shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

W World beats BriaCell Therapeutics on 4 of the 4 factors compared between the two stocks.

Wellness Center USA (OTCMKTS:WCUI) and W World (OTCMKTS:WWHC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares Wellness Center USA and W World's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wellness Center USA$30,000.00136.93$-2,390,000.00N/AN/A
W WorldN/AN/AN/AN/AN/A

W World has lower revenue, but higher earnings than Wellness Center USA.

Risk and Volatility

Wellness Center USA has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, W World has a beta of 1.97, meaning that its share price is 97% more volatile than the S&P 500.

Profitability

This table compares Wellness Center USA and W World's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wellness Center USAN/AN/A-1,809.19%
W WorldN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations for Wellness Center USA and W World, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wellness Center USA0000N/A
W World0000N/A

Institutional & Insider Ownership

0.1% of Wellness Center USA shares are held by institutional investors. Comparatively, 0.1% of W World shares are held by institutional investors. 14.1% of Wellness Center USA shares are held by insiders. Comparatively, 61.1% of W World shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

W World beats Wellness Center USA on 4 of the 5 factors compared between the two stocks.


W World Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Pivotal Therapeutics logo
PVTTF
Pivotal Therapeutics
0.6$0.08+48.8%$7.15 millionN/A0.00Gap Down
KAYS
Kaya
0.7$0.44+1.1%$6.89 million$1.01 million0.00Gap Down
Intellipharmaceutics International logo
IPCIF
Intellipharmaceutics International
0.6$0.24+12.5%$5.57 million$3.48 million-1.96Gap Down
International Stem Cell logo
ISCO
International Stem Cell
0.8$0.73+0.0%$5.50 million$9.47 million0.00Gap Up
BCTXF
BriaCell Therapeutics
0.0$5.95+1.3%$4.59 millionN/A-0.01
Wellness Center USA logo
WCUI
Wellness Center USA
0.5$0.04+30.6%$4.56 million$30,000.000.00Gap Up
American Bio Medica logo
ABMC
American Bio Medica
0.5$0.11+4.2%$4.38 million$3.65 million0.00
AMBS
Amarantus BioScience
0.0$0.01+16.8%$4.37 millionN/A0.00Gap Down
FutureWorld logo
FWDG
FutureWorld
0.5$0.00+0.0%$3.80 millionN/A0.00Gap Up
AKRXQ
Akorn
0.1$0.03+0.7%$3.60 million$682.43 million-0.01
VGLS
VG Life Sciences
0.0$0.01+2.7%$3.50 millionN/A0.00Gap Down
Boston Therapeutics logo
BTHE
Boston Therapeutics
0.5$0.03+3.7%$3.00 million$20,000.00-1.35Gap Up
INNVD
Innovus Pharmaceuticals
0.6$3.00+59.0%$2.90 million$23.99 million-0.72Gap Down
RSPI
RespireRx Pharmaceuticals
0.5$0.04+8.5%$2.76 millionN/A-0.08
NSPX
Inspyr Therapeutics
0.5$0.01+2.0%$2.21 millionN/A0.00
VVUSQ
VIVUS
0.6$0.12+1.5%$2.10 million$69.76 million-0.04
IMUCD
ImmunoCellular Therapeutics
0.0$0.31+11.3%$2.10 millionN/A0.00Gap Down
Capstone Therapeutics logo
CAPS
Capstone Therapeutics
0.8$34.00+5.9%$1.84 million$2 million0.00Gap Down
ImmunoCellular Therapeutics logo
IMUC
ImmunoCellular Therapeutics
0.0$0.50+25.8%$1.76 millionN/A0.00Gap Up
Cardax logo
CDXI
Cardax
0.0$2.10+4.8%$1.67 million$710,000.000.00
Earth Science Tech logo
ETST
Earth Science Tech
0.5$0.03+7.0%$1.54 million$530,000.000.00Gap Down
MLNTQ
Melinta Therapeutics
0.2$0.11+7.9%$1.51 million$96.43 million0.00Gap Up
Achaogen logo
AKAOQ
Achaogen
0.6$0.02+12.2%$1.30 million$8.73 million0.00
AOLS
Aeolus Pharmaceuticals
0.8$0.01+15.4%$1.19 millionN/A0.00Gap Down
Cotinga Pharmaceuticals logo
COTQF
Cotinga Pharmaceuticals
0.4$0.05+388.2%$1.12 millionN/A-0.57Upcoming Earnings
High Trading Volume
Propanc Biopharma logo
PPCB
Propanc Biopharma
0.7$0.24+4.8%$1.12 millionN/A0.00
ATRX
Adhera Therapeutics
0.0$0.09+17.6%$1.11 million$250,000.000.00Gap Up
TetraLogic Pharmaceuticals logo
TLOG
TetraLogic Pharmaceuticals
0.5$0.04+14.9%$1.08 millionN/A0.00Gap Up
AOXG
Aoxing Pharmaceutical
0.5$0.01+1.4%$1.05 millionN/A0.00
Immune Pharmaceuticals logo
IMNPQ
Immune Pharmaceuticals
0.0$0.05+16.9%$1.03 millionN/A0.00Gap Down
SPHS
Sophiris Bio
0.1$0.03+8.8%$1.01 millionN/A0.00Gap Down
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.07+11.0%$996,000.00N/A0.00Gap Down
PXYN
Praxsyn
0.6$0.00+25.0%$848,000.00N/A0.00Gap Up
STLT
Spotlight Innovation
0.5$0.02+55.6%$772,000.00N/A0.00Gap Down
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03+29.2%$771,000.00N/A0.00
SKVI
Skinvisible
0.7$0.15+0.0%$671,000.00$40,000.000.00
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05+16.0%$572,000.00$1.90 million0.00
TRPXD
Therapix Biosciences
0.0$5.98+51.8%$454,000.00N/A0.00Gap Up
BSPM
Biostar Pharmaceuticals
0.0$0.17+12.1%$436,000.00N/A0.00Gap Up
HSTC
HST Global
0.8$0.07+108.3%$378,000.00N/A0.00High Trading Volume
Gap Down
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.02+25.3%$366,000.00N/A0.00Gap Down
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47+3.7%$338,000.00$36.55 million0.00Gap Up
WDBG
Woodbrook Group
0.0$1.48+14.2%$207,000.00N/A0.00Gap Down
ROSGQ
Rosetta Genomics
0.0$0.07+3.7%$119,000.00N/A0.00Gap Down
MetaStat logo
MTST
MetaStat
0.0$0.02+30.0%$118,000.00$20,000.000.00Gap Down
PZRXQ
PhaseRx
0.2$0.01+21.7%$108,000.00N/A0.00Gap Down
OREXQ
Orexigen Therapeutics
0.4$0.01+26.4%$100,000.00$33.71 million0.00Gap Up
AXMP
AXM Pharma
0.2$0.00+150.0%$81,000.00N/A0.00Gap Up
ALSE
Alseres Pharmaceuticals
0.0$6.00+0.0%$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00+0.0%$20,000.00N/A0.00
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.